Angela Bellini et al.
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
Journal of Clinical Oncology 2021, vol. 39, issue 30
doi: 10.1200/jco.21.00086
![Logo France Génomique](https://www.france-genomique.org/wp-content/uploads/2019/03/logo-FG-blue-RVB-medium.png)